Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 8/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038642 | 0.85 | PPARA (0.54) | PPARACYP1A2CYP3A4TSHRPPARG | |
| SCHEMBL3483913 | 0.85 | PPARA (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3900554 | 0.84 | PPARA (0.68) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3484509 | 0.81 | PPARA (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3484747 | 0.80 | PPARA (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3483926 | 0.79 | FBP1 (0.41) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3484192 | 0.78 | PPARA (0.59) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3484819 | 0.77 | FBP1 (0.47) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL6091395 | 0.76 | PPARA (0.69) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3483710 | 0.76 | PPARA (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | FBP1 2382/4885PPARA 1045/4885ABCB11 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.